Secondary acute myeloid leukemia with inv(16): Report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy

Leukemia

Volumn 13, Issue 11, 1999, Pages 1735-1740

  Seymour, J F ^a   Juneja, S K ^a   Campbell, L J ^b   Ellims, P H ^c   Estey, E H ^d   Prince, H M ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c Epworth Freemasons Hospital   (Australia)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

High dose cytosine arabinoside; inv(16); Paclitaxel; Secondary leukemia

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; PACLITAXEL;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHROMOSOME INVERSION; CLINICAL ARTICLE; DISEASE PREDISPOSITION; FEMALE; GENDER; HUMAN; HUMAN CELL; INTRATHECAL DRUG ADMINISTRATION; MALE; OVARY CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0032718334     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401552     Document Type: Article

References (43)

1. Rowley JD, Golomb HM, Vardiman JW. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood 1981; 58: 759-767.
2. Pedersen-Bjergaard J, Larsen SO. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. New Engl J Med 1982; 307: 965-971.
3. Smith MA, McCaffrey RP, Karp JE. The secondary leukemias: challenges and research directions. J Natl Cancer Inst 1996; 88: 407-418.
4. McCabe NR, Burnett RC, Gill HJ, Thirman MJ, Mbangkollo D, Kipiniak M, van Melle E, Ziemin-van der Poel S, Rowley JD, Diaz MO. Cloning of cDNAs of the MLL gene that detect DNA rearrangements and altered RNA transcripts in human leukemic cells with 11q23 translocations. Proc Natl Acad Sci USA 1992; 89: 11794-11798.
5. Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, Head DR, Behm FG, Mahmoud MH, Sandlund JT, Crist WM. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. New Engl J Med 1991; 325: 1682-1687.
6. Kantarjian HM, Keating MJ, Walters RS, Beran M, McLaughlin P, McCredie KB, Freireich EJ. The association of specific 'favorable' cytogenetic abnormalities with secondary leukemia. Cancer 1986; 58: 924-927.
7. Fenaux P, Lucidarme D, Laï JL, Bauters F. Favorable cytogenetic abnormalities in secondary leukemia. Cancer 1989; 63: 2505-2508.
8. Hoyle CF, de Bastos M, Wheatley K, Sherrington PD, Fischer PJ, Rees JKH, Gray R, Hayhoe FCJ. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. Br J Haematol 1989; 72: 45-53.
9. Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersboll J, Hansen SW, Hou-Jensen K, Nielsen D, Sigsgaard TC, Specht L, Osterlind K. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993; 7: 1975-1986.
10. Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83: 2780-2786.
11. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86: 3542-3552.
12. Quesnel B, Kantarjian H, Pedersen-Bjergaard J, Brault P, Estey E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL, Bauters F, Fenaux P. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol 1993; 11: 2370-2379.
13. Dissing M, Le Beau MM, Pedersen-Bjergaard J. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors? J Clin Oncol 1998; 16: 1890-1896.
14. Schnittiger S, Schoch C, Löffler H, Büchner T, Haferlach T, Hiddemann W. Uncommon CBFb-MYH 11 transcripts are more frequent in therapy related AML M4eo than in de novo M4eo. Blood 1998; 92 (Suppl. 1): 78a (Abstr. 317).
15. Ghaddar HM, Plunkett W, Kantarjian HM, Pierce S, Freireich EJ, Keating MJ, Estey EH. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia 1994; 8: 1269-1274.
16. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantaravavhi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173-4179.
17. Linassier C, Barin C, Brémond JL, Benboubker L, Petit A, Georegt MT, Delain M, Binet C, Lamagnère JP, Colombat P. Secondary leukemia in breast cancer patients after exposure to an association of mitoxantrone, fluorouracil and cyclophosphamide and radiotherapy. Proc Am Soc Clin Oncol 1996; 15: 360 (Abstr. 1061).
18. Harrison CN, Vaughan Hudson G, Devereux S, Linch DC. Outcome of secondary myeloid malignancy in Hodgkin's disease: the BNL1 experience. Eur J Haematol 1998; 61: 109-112.
19. Whang-Peng J, Young RC, Lee EC, Longo DL, Schechter GP, DeVita VT Jr. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 1988; 71: 403-414.
20. Yagita M, Ieki Y, Onishi R, Huang CL, Adachi M, Horiike S, Konaka Y, Taki T, Miyake M. Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer. In J Oncol 1998; 13: 91-96.
21. Grois N, Nowotny H, Tyl E, Krieger O, Kier P, Haas OA. Is trisomy 22 in acute myeloid leukemia a primary abnormality or only a secondary change associated with inversion 16? Cancer Genet Cytogenet 1989;43: 119-129.
22. Sozzi G, Miozzo M, Orazi A, Calderone C, Castellano M, Viviani S, Santoro A, Pierotti MA, Della Porta G. Cytogenetic study in therapy-related myelodysplatic syndromes (t-MDS) and acute nonlymphocytic leukemia (t-ANLL). Br J Cancer 1990; 61: 425-428.
23. Larson RA, Wernli M, Le Beau MM, Daly KM, Pape LH, Rowley JD, Vardiman JW. Short remission durations in therapy-related leukemia despite cytogenetic complete response to high-dose cytarabine. Blood 1988; 72:1333-1339.
24. Jones DB, Kaye F, Hardman J, Whang-Peng J, Dale NL, Garvin DF, Schumacher HR. The eosinophilic variant of acute myelomonocyitc leukemia developing as a secondary leukemia in a patient with mycosis fungoides. Hematol Pathol 1987; 1: 67-76.
25. Larson RA, Le Beau MM, Ratain MJ, Rowley JD. Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia. Blood 1992; 79: 1892-1893.
26. Baglin TP, Glavin GP, Pollock A. Therapy-related acute nonlymphocytic leukemia with inversion of chromosome 16 and a sustained remission. Cancer Genet Cytogenet 1987; 27: 167-169.
27. Pui CH, Behm FG, Raimondi SC, Dodge RK, George SL, Rivera GK, Mirro J Jr, Kalwinsky DK, Dahl GV, Murphy SB, Crist WM, Williams DL. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. New Engl J Med 1989; 321: 136-142.
28. Fenaux P, Laï JL, Quiquandon I, Preudhomme C, Dupriez B, Facon T, Lorthois C, Lucidarme D, Bauters F. Therapy related myelodysplastic syndrome and leukemia with no 'unfavorable' cytogenetic findings have a good response to intensive chemotherapy: a report on 15 cases. Leuk Lymphoma 1991; 5: 117-125.
29. Estey E, Trujillo JM, Cork A, O'Brien S, Beran M, Kantarjian H, Keating M, Freireich EJ, Stass S. AML-associated cytogenetic abnormalities (inv(16), del(16), t(8;21)) in patients with myelodysplastic syndromes. Hematol Pathol 1992; 6: 43-48.
30. Pedersen-Bjergaard J, Andersen MK, Johansson B. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J Clin Oncol 1998; 16: 1897-1898.
31. Larson RA, Williams SF, Le Beau MM, Bitter MA, Vardiman JW, Rowley JD. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood 1986; 68: 1242-1249.
32. Betts DR, Rohatiner AZS, Evans ML, Rassam SMB, Lister TA, Gibbons B. Abnormalities of chromosome 16q in myeloid malignancy: 14 new cases and a review of the literature. Leukemia 1992; 6: 1250-1256.
33. Campbell LJ, Challis J, Fok T, Garson OM. Chromosome 16 abnormalities associated with myeloid malignancies. Genes Chromosomes Cancer 1991; 3: 55-61.
34. Kaldor JM, Day NE, Pettersson F, Clarke EA, Pedersen D, Mehnert W, Bell J, Host H, Prior P, Karjalainen S, Neal F, Koch M, Band P, Choi W, Kim VP, Arslan A, Zarén B, Belch AR, Strom H, Kittelmann B, Fraser P, Stovall M. Leukemia following chemotherapy for ovarian cancer. New Engl J Med 1990; 322: 1-6.
35. Cheruku R, Hussain M, Tyrkus M, Edelstein M. Myelodysplastic syndrome after cisplatin therapy. Cancer 1993; 72: 213-218.
36. Travis LB, Holowaty EJ, Bergfeldt K, Lynch CF, Kohler BA, Wiklund T, Curtis RE, Hall P, Anderson M, Pukkala E, Strugeon J, Stovall M, Storm H, Clarke A, Boice JD Jr, Gospodarowicz M. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. New Engl J Med 1999; 340: 351-357.
37. Juneja SK, Matthews JP, Luzinat R, Fan Y, Michael M, Rischin D, Millward MJ, Toner GC. Association of acquired Pelger-Huet anomaly with taxoid therapy. Br J Haematol 1996; 93: 139-141.
38. Harrison BR. Safe handling of cytotoxic drugs. In: Perry MC (ed). The Chemotherapy Source Book, 2nd edn. Williams & Wilkins: Baltimore, 1997, pp 905-945.
39. Ballen KK, Antin JH. Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes. Hematol Oncol Clin N Am 1993; 7: 477-493.
40. Holmes R, Keating MJ, Cork A, Broach Y, Trujillo J, Dalton WT Jr, McCredie KB, Freireich EJ. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood 1985; 65: 1071-1078.
41. Marlton P, Keating M, Kantarjian H, Pierce S, O'Brien S, Freireich EJ, Estey E. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia 1995; 9: 965-971.
42. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322-2333.
43. Tosi P, Visani G, Ottaviani E, Testoni N, Pellacani A, Tura S. Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro. Eur J Haematol 1998; 60: 161-165.